Tranzyme, which is developing small molecule therapeutics to treat gastrointestinal disorders, raised $54 million by offering 13.5 million shares at $4. The biotech had originally filed to raise $60 million by offering 5 million shares at a range of $11 to $13. Tranzyme plans to list on the NASDAQ on Monday under the symbol TZYM. Citi acted as lead manager on the deal.
